Macrogenics, Inc. share price today

(MGNX)

Macrogenics, Inc. share price is $3.5 & ₹296.25 as on 7 Dec 2024, 2.30 'hrs' IST

$3.5

▲

0.11

(3.24%)

Market is closed - opens 8 PM, 09 Dec 2024

View live Macrogenics, Inc. share price in Dollar and Rupees. Guide to invest in Macrogenics, Inc. from India. Also see the sentimental analysis on Indian investors investing in Macrogenics, Inc.. Get details on the Indian mutual funds that are investing in Macrogenics, Inc.. Get Analyst recommendations and forecasts along with all the Macrogenics, Inc.'s financials.

Macrogenics, Inc. share price movements

$3.37
$3.54
$3.50
3.71%
Downside
Day's Volatility :4.8%
Upside
1.13%
$2.95
$21.88
$3.50
15.68%
Downside
52 Weeks Volatility :86.51%
Upside
84.0%

Macrogenics, Inc. Returns

Period	Macrogenics, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-1.74%	-5.7%	0.0%
6 Months	-25.98%	-0.8%	0.0%
1 Year	-61.08%	9.9%	0.0%
3 Years	-80.74%	10.7%	-19.7%

Macrogenics, Inc. Key Statistics

in dollars & INR

Previous Close	$3.39
Open	$3.41
Today's High	$3.54
Today's Low	$3.37
Market Capitalization	$212.8M
Today's Volume	$474.0K
52 Week High	$21.88
52 Week Low	$2.9511
Revenue TTM	$141.3M
EBITDA	$-99.7M
Earnings Per Share (EPS)	$-1.57
Profit Margin	-69.07%
Quarterly Earnings Growth YOY	2.21%
Return On Equity TTM	-62.17%

How to invest in Macrogenics, Inc. from India?

It is very easy for Indian residents to invest directly in Macrogenics, Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Macrogenics, Inc. stock in both rupees (INR) and dollars (USD). Search for Macrogenics, Inc. or MGNX on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Macrogenics, Inc. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Macrogenics, Inc. shares which would translate to 0.242 fractional shares of Macrogenics, Inc. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Macrogenics, Inc.

80%

Period: Sep 7, 2024 to Dec 6, 2024. Change in 30 Days versus previous period

Search volume for Macrogenics, Inc. on INDmoney from India has grown in the last 30 days as on Dec 7, 2024. 80% more investors are searching Macrogenics, Inc. in the last 30 days versus the previous period.

Global Institutional Holdings in Macrogenics, Inc.

Bellevue Group AG
15.82%
Armistice Capital, LLC
9.97%
BlackRock Inc
8.61%
Vanguard Group Inc
6.94%
Millennium Management LLC
5.63%
Wasatch Advisors LP
4.04%

Analyst Recommendation on Macrogenics, Inc.

Buy

88%Buy

11%Hold

0%Sell

Based on 18 Wall street analysts offering stock ratings for Macrogenics, Inc.(by analysts ranked 0 to 5 stars)

Based on 18 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Macrogenics, Inc.

What analysts predicted

Upside of 110.71%

Current:

$3.50

Target:

$7.38

Insights on Macrogenics, Inc.

Increasing Revenue
Revenue is up for the last 3 quarters, 9.10M → 110.70M (in $), with an average increase of 53.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -55.66M → 56.30M (in $), with an average increase of 198.9% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 43.9% return, outperforming this stock by 104.7%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 42.3% return, outperforming this stock by 122.0%

Macrogenics, Inc. Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$60.1M	↓ 61.34%
Net Income	$-171.5M	↑ 773.6%
Net Profit Margin	-285.18%	↓ 272.56%

	FY19	Y/Y Change
Revenue	$62.0M	↑ 3.17%
Net Income	$-151.8M	↓ 11.46%
Net Profit Margin	-244.76%	↑ 40.42%

	FY20	Y/Y Change
Revenue	$97.8M	↑ 57.62%
Net Income	$-117.8M	↓ 22.42%
Net Profit Margin	-120.48%	↑ 124.28%

	FY21	Y/Y Change
Revenue	$75.6M	↓ 22.63%
Net Income	$-190.9M	↑ 62.04%
Net Profit Margin	-252.31%	↓ 131.83%

	FY22	Y/Y Change
Revenue	$151.9M	↑ 100.87%
Net Income	$-120.0M	↓ 37.11%
Net Profit Margin	-78.99%	↑ 173.32%

	FY23	Y/Y Change
Revenue	$58.7M	↓ 61.33%
Net Income	$-9.1M	↓ 92.45%
Net Profit Margin	-15.42%	↑ 63.57%

	Q2 FY23	Q/Q Change
Revenue	$13.1M	↓ 45.75%
Net Income	$57.5M	↓ 250.25%
Net Profit Margin	437.49%	↑ 595.45%

	Q3 FY23	Q/Q Change
Revenue	$10.4M	↓ 20.85%
Net Income	$17.6M	↓ 69.45%
Net Profit Margin	168.84%	↓ 268.65%

	Q4 FY23	Q/Q Change
Revenue	$10.7M	↑ 3.11%
Net Income	$-46.1M	↓ 362.46%
Net Profit Margin	-429.78%	↓ 598.62%

	Q1 FY24	Q/Q Change
Revenue	$9.1M	↓ 15.07%
Net Income	$-52.2M	↑ 13.28%
Net Profit Margin	-573.26%	↓ 143.48%

	Q2 FY24	Q/Q Change
Revenue	$10.8M	↑ 18.6%
Net Income	$-55.7M	↑ 6.66%
Net Profit Margin	-515.55%	↑ 57.71%

	Q3 FY24	Q/Q Change
Revenue	$110.7M	↑ 925.36%
Net Income	$56.3M	↓ 201.16%
Net Profit Margin	50.86%	↑ 566.41%

	FY18	Y/Y Change
Total Assets	$332.1M	↓ 11.17%
Total Liabilities	$89.3M	↑ 19.57%

	FY19	Y/Y Change
Total Assets	$312.5M	↓ 5.91%
Total Liabilities	$81.9M	↓ 8.27%

	FY20	Y/Y Change
Total Assets	$378.7M	↑ 21.2%
Total Liabilities	$82.9M	↑ 1.2%

	FY21	Y/Y Change
Total Assets	$335.2M	↓ 11.48%
Total Liabilities	$95.6M	↑ 15.41%

	FY22	Y/Y Change
Total Assets	$280.5M	↓ 16.34%
Total Liabilities	$138.5M	↑ 44.79%

	FY23	Y/Y Change
Total Assets	$298.4M	↑ 6.4%
Total Liabilities	$145.8M	↑ 5.31%

	Q2 FY23	Q/Q Change
Total Assets	$305.7M	↓ 11.02%
Total Liabilities	$134.1M	↓ 42.74%

	Q3 FY23	Q/Q Change
Total Assets	$340.0M	↑ 11.23%
Total Liabilities	$146.0M	↑ 8.86%

	Q4 FY23	Q/Q Change
Total Assets	$298.4M	↓ 12.22%
Total Liabilities	$145.8M	↓ 0.13%

	Q1 FY24	Q/Q Change
Total Assets	$248.3M	↓ 16.8%
Total Liabilities	$142.1M	↓ 2.52%

	Q2 FY24	Q/Q Change
Total Assets	$201.1M	↓ 18.99%
Total Liabilities	$143.3M	↑ 0.84%

	Q3 FY24	Q/Q Change
Total Assets	$264.5M	↑ 31.5%
Total Liabilities	$144.4M	↑ 0.77%

	FY18	Y/Y Change
Operating Cash Flow	$-153.2M	↓ 1163.76%
Investing Cash Flow	$56.6M	↓ 27.26%
Financing Cash Flow	$105.0M	↑ 197.02%

	FY19	Y/Y Change
Operating Cash Flow	$-134.3M	↓ 12.38%
Investing Cash Flow	$-79.4M	↓ 240.1%
Financing Cash Flow	$120.0M	↑ 14.27%

	FY20	Y/Y Change
Operating Cash Flow	$-111.9M	↓ 16.66%
Investing Cash Flow	$-7.8M	↓ 90.19%
Financing Cash Flow	$174.3M	↑ 45.32%

	FY21	Y/Y Change
Operating Cash Flow	$-143.8M	↑ 28.54%
Investing Cash Flow	$-36.6M	↑ 370.25%
Financing Cash Flow	$122.8M	↓ 29.58%

	FY22	Y/Y Change
Operating Cash Flow	$-87.0M	↓ 39.54%
Investing Cash Flow	$70.7M	↓ 293.16%
Financing Cash Flow	$1.7M	↓ 98.65%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-2.1M	↓ 83.72%
Investing Cash Flow	$-113.5M	↓ 503.9%
Financing Cash Flow	$59.0K	↓ 99.94%

Macrogenics, Inc. Technicals Summary

Sell

Neutral

Buy

Macrogenics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Macrogenics, Inc. Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Macrogenics, Inc.	-19.09%	-25.98%	-61.08%	-80.74%	-65.51%
Regeneron Pharmaceuticals, Inc.	-5.97%	-23.34%	-8.6%	17.41%	110.02%
Biontech Se	11.44%	21.29%	14.9%	-59.29%	309.79%
Alnylam Pharmaceuticals, Inc.	-7.77%	64.08%	48.09%	42.33%	108.61%
Vertex Pharmaceuticals Incorporated	-6.83%	-4.83%	31.35%	122.6%	109.65%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Macrogenics, Inc.	25.32	NA	0.01	-1.38	-0.62	-0.22	NA	1.91
Regeneron Pharmaceuticals, Inc.	18.56	18.56	1.12	44.92	0.17	0.07	NA	272.04
Biontech Se	160.8	NA	0.04	-3.06	-0.02	-0.01	NA	79.73
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.19	-15.01	-0.03	NA	0.25
Vertex Pharmaceuticals Incorporated	32.84	NA	1.21	0.54	-0.03	0.12	NA	60.65

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Macrogenics, Inc.	Buy	$212.8M	-65.51%	25.32	-69.07%
Regeneron Pharmaceuticals, Inc.	Buy	$82.9B	110.02%	18.56	33.61%
Biontech Se	Buy	$28.5B	309.79%	160.8	-15.36%
Alnylam Pharmaceuticals, Inc.	Buy	$32.7B	108.61%	NA	-15.86%
Vertex Pharmaceuticals Incorporated	Buy	$118.4B	109.65%	32.84	-4.51%

About Macrogenics, Inc.

a career at macrogenics could be waiting for you! please click on "careers" ---------------------------->>> to learn more. macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. macrogenics creates both differentiated molecules that are directed to novel cancer targets, as well as “bio-betters,” which are drugs designed to improve upon marketed medicines. the combination of macrogenics’ technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. these are exciting times at macrogenics and we hope that you will take the opportunity to learn more about our organization, our pipeline and to view our job opportunities!

Organization	Macrogenics, Inc.
Employees	339
CEO	Dr. Scott Koenig M.D., Ph.D.
Industry	Health Technology

Management People of Macrogenics, Inc.

Name	Title
Dr. Scott Koenig M.D., Ph.D.	President, CEO & Director
Mr. James Karrels	Senior VP, CFO & Corporate Secretary
Dr. Stephen L. Eck M.D., Ph.D.	Senior VP of Clinical Development & Chief Medical Officer
Mr. Eric Blasius Risser	Chief Operating Officer
Dr. Thomas M. Spitznagel Ph.D.	Senior Vice President of Technical Operations
Dr. Ezio Bonvini M.D.	Senior VP of Research & Chief Scientific Officer
Mr. Jeffrey Stuart Peters J.D.	Senior VP, General Counsel & Corporate Compliance Officer
Ms. Lynn Cilinski	VP, Controller & Treasurer

Important FAQs about investing in Macrogenics, Inc. from India :

What is Macrogenics, Inc. share price today?

Macrogenics, Inc. (MGNX) share price today is $3.50.

Can Indians buy Macrogenics, Inc. shares?

Yes, Indians can invest in the Macrogenics, Inc. (MGNX) from India.

With INDmoney, you can buy Macrogenics, Inc. at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Macrogenics, Inc. at zero transaction cost.

How can I buy Macrogenics, Inc. shares from India?

It is very easy to buy Macrogenics, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Macrogenics, Inc. be purchased?

Yes, you can buy fractional shares of Macrogenics, Inc. with INDmoney app.

What are the documents required to start investing in Macrogenics, Inc. stocks?

To start investing in Macrogenics, Inc., You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.